Skip to Content
fimea-frontpage-hidden-title fimea-frontpage-hidden-title
Select search type
Move to advanced medicine search

Kieliversion valinta

  • Valitse kieli Suomi
  • Välj språket Svenska
  • Select language English
Contact Information
fimea-frontpage-hidden-title fimea-frontpage-hidden-title

Kieliversion valinta

  • Valitse kieli Suomi
  • Välj språket Svenska
  • Select language English
  •   For public
    • What is a medicine?
      • Generic substitution
      • Generic products
        • Frequently asked questions
    • What is a biosimilar?
      • Frequently asked questions about biological drugs and biosimilars
    • What is a food supplement?
    • Safety of medicines
      • Monitoring the safety of medicinal products
      • Adverse reactions
      • Submitting a report on an adverse reaction
      • Medicinal products under additional monitoring
      • Product defects
      • Drug interactions
      • Pharmaceutical injuries
    • Correct use of medicines
      • Ensure the safety of your medication
      • Instructions for the safe use of medicines
      • Monitor the effects of your medication
      • How to store medicines?
      • How should medicines be disposed of?
    • List of medicines
    • Where can I find reliable information about medicines?
      • How can I assess the reliability of drug information?
      • Medicinal product packs
      • Package leaflet
    • How are medicines supplied to users in Finland?
      • What factors affect the availability of medicines?
      • Why might a pharmacy run out of my medicine?
      • Obligatory storing of medicines
      • Exemptions and special permits
    • Ordering medicines online
      • Why is the food supplement I ordered considered to be a medicine?
    • Medicines for children
      • Developing better medicines for children
      • Collaboration on medicines education
    • Medication of the elderly
    • What medicines can I bring abroad?
    • Pain relievers and self-care
    • Bringing medicines to Finland
      • Fimea’s services to citizens
        • Cooperation with patient associations
    • Influenza
      • Influenza vaccinations
      • Antiviral medication
      • Pandemic
    • Vaccines
    • Falsified medicines
    • Medicines and pregnancy
    • Pharmaceuticals and the environment
    • Antimicrobial resistance
    • Medicines that have marketing authorisation in Finland
  •   Current events
    • Substitution of biological medicines
      • Information for medicine users
      • Information for health care professionals
    • National medicines data repository
    • Fimea and wellbeing services counties
    • Coronavirus (COVID-19)
      • Frequently asked questions (COVID-19)
      • Adverse reactions reported on corona vaccines
    • Russian attack on Ukraine
    • News archive
    • Subscribe newsletter
  •   Databases and registers
    • FimeaWeb
    • Meds75+
      • Frequently asked questions
    • National High-Risk Medicines Classification
      • Frequently asked questions
    • Consumption
    • Self-medication products
    • Basic register
      • Plasma-derived products with marketing authorisation
    • Substitutable medicinal products
      • Textfile for databases
      • Criteria used in compiling the list
    • ATC codes
    • Shortages
  •   Development and HTA
    • Assessment of pharmacotherapies (HTA)
      • Assessment of hospital-only medicinal products
      • Topic selection
      • Nordic collaboration through JNHB
      • Assessment reports (in Finnish)
    • Medicines information
      • National Medicines Information Network
      • Materials of the Medicines Information Network
    • Medication Therapy Indicators
      • Use of Avoidable Medications in the Elderly
      • Significant Polypharmacy in the Elderly
      • Drug Expenses for the Elderly
    • Patient advisory board
    • Research
      • Research Network for Rational Pharmacotherapy (RATTI)
      • Medicines Barometer
  •   Marketing authorisations
    • Marketing authorisation application
      • Finland as a Reference Member State in the decentralised procedure (DCP)
      • Finland as a Reference Member State in the Mutual Recognition / Repeat Use Procedure (MRP/RUP)
      • Changing of Reference Member State duties to Finland
      • Finland as a rapporteur in the centralised marketing authorisation procedure (CP)
      • Granted and cancelled marketing authorisations
      • Pending marketing authorisation applications
      • Biological Medicinal Products
      • Orphan drugs
      • Paediatric medicines
      • European Pharmacopoeia
      • Active substance names and standard terms
    • Product Information
      • Summary of product characteristics
      • Package leaflet
      • Package labelling
      • Text templates
      • Braille and package leaflets for the visually impaired
      • Trade names of medicinal products
      • Strength
      • Translating influenza vaccines in Finland
    • Electronic marketing authorisation submissions
      • What's new
      • Instructions for electronic marketing authorisation submissions
      • Special characteristics of the electronic marketing authorisation process for veterinary medicines
    • Introduction to market
    • Shortage notifications
      • Frequently asked questions about reporting shortages
    • Innovation Office
      • Informal Regulatory Guidance
      • Scientific Advice
      • SNSA advice
    • Safety features
    • Other permits
      • Exemption
    • Interchangeable medicinal products
    • Herbal remedies and medicinal products
      • Herbal medicinal products
      • Traditional herbal medicinal products
      • Homeopathic and anthroposophic preparations
    • Parallel import
    • Cancelling a marketing authorisation or registration and sunset clause
      • Cancelling a marketing authorisation or registration
      • Expiration of marketing authorisations and registrations (sunset clause)
      • Sunset clause - concepts
      • Sunset clause exemption
      • List of expired marketing authorisations and registrations
    • Renewals and variation applications
      • Renewals
      • Variation applications
      • Changes to labelling
      • Transferring a marketing authorisation to a new holder
      • Article 5 classification requests for variation applications
      • OTC application
    • Frequently asked questions about marketing authorisations
  •   Medical devices
    • What are medical devices?
      • Definition of medical devices
      • Special device groups
        • Software
        • Biomaterials
        • Nanomaterials
      • How to identify a medical device?
    • Topical information about devices
      • Fees for medical devices
    • Notifications and applications
      • Certificate of free sale
      • Derogation
    • Incident reports
    • Device and operator registrations
      • Device and operator notifications to Eudamed
      • Device and operator notifications to CERE
      • Details of registered operators
    • Legislation related to medical devices
    • Device manufacturers
      • Intended purpose and classification
      • General safety and performance requirements
      • Clinical evaluation and clinical investigations
      • Conformity assessment
      • CE marking
      • Labelling and instructions for use
      • Post-market surveillance
        • System and plan
        • Reports to be prepared
      • Manufacturer's incident reporting procedure
        • Incident report
          • IMDRF codes
    • Device distributors and importers
      • Importers
      • Distributors
        • Distributors' obligations
        • National language requirements
        • Reporting of incidents
        • Import to Finland of at-home tests
      • Repackaging and making of translations
    • Products without a medical purpose
    • Investigations with devices
      • Clinical investigations of devices
      • Performance studies of IVD-devices
      • Medical Device Advisory Clinic
      • Combination studies
    • Notified bodies
      • Designation of notified bodies
      • Supervision of notified bodies
      • Devices subject to specific additional procedures
    • Marketing of medical devices
  •   Pharmaceutical safety and information
    • Pharmaceutical safety
      • Reporting adverse reactions
    • Biological medicinal products
      • Advanced Therapy Medicinal Products
    • Biosimilars
      • Biosimilars in Finland
      • The position of Fimea towards interchangeability of biosimilars
    • Regulation on Medicinal Products for Paediatric Use
      • Paediatric Committee
      • Paediatric Investigation Plan
      • Coordination and communication
      • Rewards and incentives
      • Symbol in the labels of medicinal products
  •   Pharmacies
    • Pharmacy licences
      • How to apply for a pharmacy licence
      • How to apply for a subsidiary pharmacy licence
      • Supervision Committee
      • Change of pharmacist situations
    • Pharmacy tax
    • Special permits
      • Applying for a special permit – Information for prescribers
      • Applying for a special permit – Information for the releasing party
      • Decision on the special permit, processing times and fees
      • Fixed-term special permits
      • Search for medicinal products requiring a special permit
      • Frequently Asked Questions
    • Manufacturing medicinal products
    • Schengen certificates
    • PIC/S GMP Guide
    • Dose-dispensing
  •   Supervision
    • Pharmacovigilance
      • Adverse reaction reporting (EudraVigilance)
        • Frequently asked questions about reporting adverse drug reactions (ADRs)
      • Pharmacovigilance inspections
      • Product defects
      • Summaries of risk management plans
      • Additional risk minimisation material for medicinal product
      • Pharmacovigilance requirements for parallel distribution and parallel import products
    • Clinical Drug Trials
      • Clinical Trials Regulation & CTIS
      • Trials under the EU Regulation
        • Trial application and modifications
      • Transition of clinical trials
      • Safety reporting in clinical trials
      • GCP inspections
      • GCP – Good Clinical Practice
      • Frequently asked questions about Clinical drug trials
    • Advertising of medicinal products
    • Classification
      • Principles of classification
      • Classification application
      • List of medicines
      • After classification
    • Pharmaceutical industry
      • Licenses
        • Local pharmaceutical wholesale license holders
      • Registered brokers of medicinal products
    • Good Laboratory Practice (GLP)
    • Obligatory storing of medicines
      • List of products to be stocked as obligatory storage
      • Notifying the obligatory storages
      • Applying for a permit to maintain lower obligatory storage levels
      • Applying for an exemption
      • Special arrangements for the fulfilment of storage obligation
    • Establishments
      • Supervising tissue establishments
      • Supervision of organ activity
    • Certificates of a Pharmaceutical Product (CPP)
      • Applying for an export certificate
    • Narcotics control
      • Additional information to be submitted with narcotics licence applications
      • Frequently asked questions
    • Batch-specific control
    • GMP certificates
    • Gene technology
      • Supervision of contained use
        • Inspection process
      • Supervision of deliberate release
      • Gene technology register
    • Laboratory of Fimea
      • National and international collaboration
    • Legislation, regulations and guidelines
      • European Pharmacopoeia
        • National pharmacopoeia documents
        • To users of the Pharmacopoeia
        • CEP Procedure
        • International Nonproprietary Names for Pharmaceutical Substances (INN)
        • Additional Pharmacopoeia materials
      • Administrative regulations and guidelines
    • Blood services
      • Licence of a Blood Establishment
      • Hospital Blood Banks
      • Hemovigilance
      • Blood as a starting material for medicines
      • Legislation on blood service activities
    • Biobanks
      • Biobank consent
      • National biobank register
      • Guidance and supervision of biobanks at Fimea
    • Tissue establishments
      • Licence for tissue establishment
      • Tissue establishment register
      • Biovigilance
      • Regulations on human tissues and cells
      • Instructions for tissue establishments
    • Supervision of cybersecurity and resilience
      • Cybersecurity
      • Resilience of critical entities
      • Frequently asked questions
  •   Veterinary
    • Marketing authorisation procedures
      • National procedure
      • Mutual recognition procedure
      • Decentralised procedure
      • Centralised procedure
      • Validity of marketing authorisations
      • Applications for variations to marketing authorisations for veterinary medicines
    • Special permits for compassionate use
      • Applying for special permit
      • FAQ
        • A Questions and answers on how to fill in the form
        • B Questions and answers regarding the technical aspects of permit application
        • C Questions and answers regarding the decision and the processing of the application
        • D Other questions and answers
      • List of special permits for veterinary medicinal products
    • Adverse effects
    • Consumption of veterinary antimicrobials
      • The European Surveillance of Veterinary Antimicrobial Consumption ESVAC
    • Clinical trials on veterinary medicinal products
      • Immunological products
    • Withdrawal period and MRL
      • What is a withdrawal period?
      • MRL
      • Horses as food-producing animals
    • Private import
  •   About us
    • Contact us
      • Change of address
      • Copyright
      • Contact
      • Personnel
      • Secure Mail
    • Open positions
    • Forms
    • Organisation
      • Strategy
      • Sustainability
      • International representation
        • International and EU cooperation
      • Fimea committees
    • Publications
    • Fees
      • Frequently asked questions about invoicing
    • Estimated processing times
    • Data requests
    • Data access authorisations
    • Open data
    • Reports of breaches in accordance with the act on whistleblower protection
    • Frequently asked questions
    • Instructions for preparing an inspection response
  • Frontpage
  • en
  • Veterinary
  • Special permits for compassionate use

  • FAQ

FAQ

  • Valitse kieliSuomeksi
  • Välj språketPå svenska

    • FAQ (Veterinary, Special permits for compassionate use)

    The Frequently asked questions of Special permit for compassionate use are divided in four parts:

    A Questions and answers on how to fill in the form

    B Questions and answers regarding the technical aspects of permit application

    C Questions and answers regarding the decision and the processing of the application

    D  Other questions and answers

    Share
    Print

    Site information

    • About us

    Quicklinks

    • Whats new
    • Contact
    • Contact information

    Follow us

    • Linkedin Linkedin
    • Twitter Twitter
    Home fimea.fi Home fimea.fi